Long-Term Survival and Biomarker Analysis Evaluating Neoadjuvant Plus Adjuvant Relatlimab (anti-LAG3) and Nivolumab (anti-PD1) in Patients With Resectable Melanoma Our study included a broad cohort of ...
Skills are having their time in the spotlight as more business leaders grapple with how to get the right skills into the places their organization needs them most. But the $8.5 trillion skills ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results